Drug
Zimberelimab clinical trials
Also written AB122 and GLS-010.
- studies test it
- 51
- open now
- 21
- in phase 3
- 6
- first study started
- 2017
Keep track of what changes. Save the zimberelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
51 studies that test it; most in 2023 (17)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2021 | 6 |
| 2022 | 8 |
| 2023 | 17 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 14
- Phase 2
- 36
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 30
Guangzhou Gloria Biosciences Co., Ltd. (7) · Arcus Biosciences, Inc. (6) · Gilead Sciences (5) · Hospices Civils de Lyon (2) · Sun Yat-sen University (2) · Memorial Sloan Kettering Cancer Center (1) · Fundación para el Progreso de la Oncología en Cantabria (1) · Nataliya Uboha (1)
Often tested with
Tested in the same studies.
Domvanalimab (15) · AB928 (10) · Sacituzumab govitecan (6) · Cisplatin (5) · Carboplatin (4) · Quemliclustat (3) · Pemetrexed (3) · Paclitaxel (3)
Studies
Open first, then newest update. How each study uses zimberelimab is read from its arms, and is right about nine times in ten.
Testing it · 51
- A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerRecruitingPhase 3Guangzhou Gloria Biosciences Co., Ltd.NCT05798819Written as GLS-010
- A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.RecruitingPhase 2Weill Medical College of Cornell UniversityNCT05024097Written as Zimberelimab (AB122)
- Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingPhase 3Taiho Pharmaceutical Co., Ltd.NCT07710885Written as Zimberelimab
- Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaRecruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT05688215Written as Zimberelimab
- Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingPhase 3Fundación GECPNCT06431633Written as Zimberelimab
- Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCRecruitingPhase 2Dana-Farber Cancer InstituteNCT07397611Written as Zimberelimab
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingPhase 2Hospices Civils de LyonNCT07337447Written as FOLFIRI + Zimberelimab + Domvanalimab
- Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT06238921Written as Zimberelimab
- Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerRecruitingPhase 2Catherine SpinaNCT05915442Written as Zimberelimab
- Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoNCT06528483Written as Sacituzumab Govitecan + Zimberelimab
- A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06155396Written as Zimberelimab
- Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic CancerNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT06166589Written as Zimberelimab
- Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer.Not yet recruitingPhase 2Obstetrics & Gynecology Hospital of Fudan UniversityNCT06128460Written as Zimberelimab
- Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Xuekui LiuNCT06107114Written as Zimberelimab
- Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACCRecruitingPhase 2Tang-Du HospitalNCT06055738Written as Zimberelimab
- SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)Not yet recruitingPhase 2Peking University Third HospitalNCT06009029Written as Zimberelimab (GLS-010)
- Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 1/2Guangzhou Gloria Biosciences Co., Ltd.NCT05978401Written as GLS-012+GLS-010
- A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's LymphomaRecruitingPhase 2Sun Yat-sen UniversityNCT05900765Written as Zimberelimab 240mg
- Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid TumorsRecruitingPhase 1/2Guangzhou Gloria Biosciences Co., Ltd.NCT05909436Written as GLS-010
- Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)RecruitingPhase 2Suzhou Municipal HospitalNCT05872724Written as Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
See all 51 studies that test zimberelimab →
Given in every arm · 17 — zimberelimab is usual care beside what is tested
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Written as Zimberelimab
- AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic CancerRecruitingPhase 1Jonsson Comprehensive Cancer CenterNCT07619313Written as Zimberelimab
- A Clinical Trial to Assess COM503 in Participants With Advanced Solid MalignanciesRecruitingPhase 1Compugen LtdNCT06759649Written as Zimberelimab
- AB122 Platform StudyRecruitingPhase 1Taiho Pharmaceutical Co., Ltd.NCT04999761Written as AB122
- Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid TumorsRecruitingPhase 1Gilead SciencesNCT06532565Written as Zimberelimab
- Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaRecruitingPhase 2Gulam ManjiNCT06048484Written as Zimberelimab
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesActive, not recruitingPhase 2Arcus Biosciences, Inc.NCT05329766Written as Zimberelimab
- Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersActive, not recruitingPhase 1Arcus Biosciences, Inc.NCT05891171Written as Zimberelimab
- A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT04104672Written as Zimberelimab
- Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Active, not recruitingPhase 2Gilead SciencesNCT06727565Written as Zimberelimab
- Study of GS-4528 in Adults With Solid TumorsActive, not recruitingPhase 1Gilead SciencesNCT05840224Written as Zimberelimab
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedPhase 2Arcus Biosciences, Inc.NCT04262856Written as Zimberelimab
- Study With Various Immunotherapy Treatments in Participants With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05676931Written as Zimberelimab
- Study of GS-9911 With or Without Antibody Treatment for Adults With Solid TumorsActive, not recruitingPhase 1Gilead SciencesNCT06082960Written as Zimberelimab
- An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.CompletedPhase 1/2Arcus Biosciences, Inc.NCT04660812Written as Zimberelimab
- Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate CancerCompletedPhase 1/2Arcus Biosciences, Inc.NCT04381832Written as Zimberelimab
- A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT03628677Written as Zimberelimab
As the comparator · 1 — what is tested is compared with zimberelimab
Codes
What other systems call zimberelimab · ClinicalTrials.gg INT001731
- MeSH (NLM) C000719848zimberelimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) ZBL7O904ILZIMBERELIMABConfirmed FDA, NLM
- NCI Thesaurus C159549ZimberelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719848 | zimberelimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | ZBL7O904IL | ZIMBERELIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C159549 | Zimberelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.